Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapeutic vaccination against human papillomavirus type 16 for the treatment of anal intraepithelial neoplasia in HIV+ men

Trial Profile

Therapeutic vaccination against human papillomavirus type 16 for the treatment of anal intraepithelial neoplasia in HIV+ men

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peltopepimut-S (Primary) ; Peginterferon alfa-2a
  • Indications Anal cancer; Anal intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VACCAIN-T
  • Sponsors ISA Pharmaceuticals

Most Recent Events

  • 13 Mar 2018 Status changed from recruiting to completed.
  • 05 Aug 2016 Planned End Date changed from 1 Feb 2018 to 1 Jan 2018.
  • 05 Aug 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top